Table 2.
Pooled follow-up visits of 1,261 RA patients divided by HCQ exposure
| None | Some Visits | All Visits | Padj* | |
|---|---|---|---|---|
| No of patients/No of visits | 836/2911 | 316/1394 | 109/300 | |
| Female, n(%) | 2127 (73) | 1,049 (75) | 239 (80) | |
| Non-Hispanic White, n(%) | 1,059 (36) | 372 (26) | 123 (40) | |
| Duration of RA, mean ± SD | 15.3 ± 10.9 | 13.3 ± 9.3 | 11.9 ± 9.5 | ≤0.001, ≤0.001 |
| Laboratory | ||||
| Total Cholesterol mg/dl, mean (SD) |
185.7 ± 40.5 | 182.0 ± 38.0 | 181.0 ± 35.8 | 0.031, 0.01 |
| LDL mg/dl, mean (SD) | 106.5 ± 33.7 | 103.0 ± 30.7 | 97.22 ± 29.8 | 0.026, <0.001 |
| HDL mg/dl, mean (SD) | 52.8 ± 16.3 | 54.5 ± 17.2 | 60.6 ± 18.4 | 0.121, <0.001 |
| Triglycerides mg/dl, mean (SD) |
131.5 ± 80.6 | 123.1 ± 63.0 | 114.7 ± 56.9 | <0.001, <0.001 |
| Total Cholesterol/HDL, mean (SD) |
3.80 ± 1.5 | 3.60 ± 1.3 | 3.21 ± 1.1 | 0.001, <0.001 |
| LDL/HDL, mean (SD) | 2.21 ± 1.1 | 2.09 ± 1.1 | 1.76 ± 0.8 | 0.04, <0.001 |
| Plasma glucose mg/dl, mean (SD) |
103.0 ± 38.7 | 101.9 ± 37.6 | 95.1 ± 30.4 | 0.77, 0.09 |
| ESR mg/dl,mean (SD) | 29.0±25.2 | 32.5±26.9 | 21.9±23.4 | 0.01, 0.04 |
| Clinical | ||||
| Tender joints, mean (SD)** | 7.45 ± 8.4 | 8.5 ± 8.7 | 6.36 ± 7.2 | 0.48, 0.31 |
| Swollen joints, mean (SD)** | 2.04 ± 3.7 | 2.51 ± 3.8 | 1.43 ± 2.8 | 0.39, 0.007 |
| Deformed joints, mean(SD)** | 8.42 ± 8.4 | 9.70 ± 8.7 | 5.69 ± 6.7 | 0.003, 0.066 |
| DAS28ESR $ | 3.99 ± 1.6 | 4.22 ± 1.6 | 3.48 ± 1.61 | 0.7, <0.001 |
| Sharp Score # | 82.5 ± 95.2 | 94.9 ± 101.3 | 46.1 ± 71.8 | 0.013, 0.009 |
| Diabetes Med, n (%) | 448 (15.4) | 249(17.9) | 47(15.7) | 0.56, 0.67 |
| Current Lipid Lowering, n(%) | 755 (25.9) | 288 (20.7) | 67 (22.4) | 0.15, 0.62 |
| Any Other DMARD, n (%) | 2141 (73.5) | 1069 (76.7) | 253 (84.3) | 0.54, 0.07 |
P-values were obtained from GEE regression models for clinical comparison, models were adjusted for age, sex, RA duration, ethnicity, bmi, smoking, and lipid and DMARD medications. For laboratory comparisons p-value were adjusted for propensity scores.
We were unable to obtain articular data at all visits on 147 patients. of these 116 patients were never exposed to HCQ; 24 were intermittently exposed; and 7 were continuously taking HCQ.
We were unable to obtain both articular data and ESR at all visits on 177: of these 134 patients were never exposed to HCQ; 33 were intermittently exposed; 10 were continuously taking HCQ.
We were unable to obtain hand radiographs at all visit on 987: of these 670 were never exposed to HCQ; 273 were intermittently exposed; 44 were continuously taking HCQ.